Tilray Brands (TLRY) Cash & Current Investments (2017 - 2026)
Tilray Brands' (TLRY) quarterly Cash & Current Investments came in at $234.6 million in Q2 2026, down 8.48% YoY from $256.4 million in Q2 2025, and up 6.68% on a QoQ basis from $219.9 million in Q1 2026.
Tilray Brands (TLRY) Cash & Current Investments (2017 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 10 years of Cash & Current Investments data on file, last reported at $234.6 million in Q2 2026.
- Quarterly Cash & Current Investments fell 8.48% year-over-year to $234.6 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $234.6 million (down 8.48% YoY) and the FY2026 annual result came in at $234.6 million, down 8.48% from the prior year.
- Cash & Current Investments grew to $234.6 million in Q2 2026, from $219.9 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $490.6 million in Q3 2022 to a low of $219.9 million in Q1 2026.
- A 5-year average of $322.7 million and a median of $279.2 million in 2022 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2023 — Cash & Current Investments jumped 46.23% — and 2024, when it tumbled 44.68%.
- Tracing TLRY's Cash & Current Investments over 5 years: stood at $433.5 million in 2022, then slumped by 40.07% to $259.8 million in 2023, then decreased by 2.9% to $252.2 million in 2024, then advanced by 15.58% to $291.6 million in 2025, then dropped by 19.52% to $234.6 million in 2026.
- The last three Cash & Current Investments figures came in at $234.6 million (Q2 2026), $219.9 million (Q1 2026), and $291.6 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 963.33 Mn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 5.80 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 2.66 Bn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 389.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 164.00 Mn |
| 10 | Tilray Brands | 513.87 Mn | 279.24 Mn | 90.52 Mn | 234.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 234.63 Mn |
| Feb 28, 2026 | 219.93 Mn |
| Nov 30, 2025 | 291.55 Mn |
| Aug 31, 2025 | 264.83 Mn |
| May 31, 2025 | 256.36 Mn |
| Nov 30, 2024 | 252.25 Mn |
| Aug 31, 2024 | 280.06 Mn |
| May 31, 2024 | 260.52 Mn |
| Feb 29, 2024 | 225.86 Mn |
| Nov 30, 2023 | 259.79 Mn |
| Aug 31, 2023 | 464.85 Mn |
| May 31, 2023 | 448.53 Mn |
| Feb 28, 2023 | 408.28 Mn |
| Nov 30, 2022 | 433.50 Mn |
| Aug 31, 2022 | 490.64 Mn |
| May 31, 2022 | 415.91 Mn |
| Feb 28, 2022 | 279.21 Mn |
| Nov 30, 2021 | 331.78 Mn |
| Aug 31, 2021 | 376.30 Mn |
| May 31, 2021 | 488.47 Mn |